glycogen phosphorylase inhibitor

Glycogen phosphorylase-IN-1 is a selective and potent inhibitor of human hepatic glycogen phosphorylase (hlGPa) with inhibitory effects on hlGPa activity and on hepatocyte glycogen-derived glucose production, and can be used in the study of type 2 diabetes mellitus and canine lupus.

AVE5688 is an inhibitor of glycogen phosphorylase (GP, IC50s: 430 nM and 915 nM; Kds: 170 nM and 530 nM for rmGPb and rmGPa). It can be used for the research of type 2 diabetes.

1,4-Dideoxy-1,4-imino-D-arabinitol (DAB) functions as an inhibitor of glycogen phosphorylase, a crucial enzyme in glycogenolysis, demonstrating the ability to hinder this process in isolated liver cells (IC50= 1.0 µM) and cerebral cortex and cerebellum homogenates (IC50s = 463 and 383 nM, respectively). Employed extensively in different animal models, DAB inhibits glycogenolysis within the liver and brain.

CP-320626 is an effective inhibitor of glycogen phosphorylase A (LGPA) in the human liver and GPA in the human muscle. Can act synergistically with glucose. It is a possible target for the treatment of type 2 diabetes.

AVE 9423 is an allosteric glycogen phosphorylase inhibitor.

Morolic acid and moronic acid have shown sustained antidiabetic and antihyperglycemic action possibly mediated by an insulin sensitization with consequent changes of glucose, cholesterol and triglycerides, in part mediated by inhibition of 11β-HSD 1. Moro

CP-316819 (GPi 819) is a potent inhibitor of glycogen phosphorylase (GPase) with hypoglycemic effects, inhibits huSMGPa and huLGPa, maintains neuronal activity during hypoglycemia, and can be used in the study of hyperglycemia.

Ingliforib (CP 368296) is a novel glycogen phosphorylase inhibitor,has antihyperglycemic and cardioprotective properties.

CP-91149 is a selective glycogen phosphorylase (GP) inhibitor with IC50 of 0.13 μM in the presence of glucose, 5- to 10-fold less potent in the absence of glucose.